ArticleComputational and structural biotechnology journal2025
Influence of PARP1 on CRISPR/Cas9 induced double strand break repair in proliferating cells.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genome editing with CRISPR/Cas9 depends on the induction of site-specific DNA double-strand breaks (DSBs), which are repaired by distinct pathways. Non-homologous end joining (NHEJ) frequently introduces insertions or deletions (indels), resulting in mutagenic repair, whereas microhomology-mediated end joining (MMEJ) produces larger deletions due to end resection. In the presence of a donor template, homologous recombination (HR) enables precise sequence changes but is generally inefficient in many cell types. Modulating the activity of key repair factors has therefore emerged as a promising strategy to bias DSB repair outcomes toward more predictable or precise edits. Here, we employed luminescent and fluorescent reporter assays to systematically quantify the impact of PARP1 modulation on repair pathway choice. We show that PARP1 downregulation increased both NHEJ and MMEJ repair without altering HR, while PARP1 overexpression reduced NHEJ and HR but left MMEJ activity unaffected. These results highlight PARP1 as a regulator of DSB repair balance and suggest that targeted modulation of PARP1 could improve the precision of CRISPR-based genome editing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.